FTC and Four States Sue WPATH Over Pediatric Gender-Affirming Care Guidelines

The Federal Trade Commission (FTC), joined by four Republican-led states, has filed a sweeping and unprecedented lawsuit against the World Professional Association for Transgender Health (WPATH), marking a significant escalation in the Trump administration's broader efforts to restrict gender-affirming care for minors. Filed on Wednesday in a Texas federal court, the lawsuit alleges that the non-profit medical organization violated federal and state consumer protection laws by making deceptive, false, and unsubstantiated claims about the safety and efficacy of pediatric medical transition services. The legal action represents a major front in the administration's campaign, shifting the battleground from state legislatures directly into the federal courts by targeting the very institution responsible for drafting the foundational clinical guidelines used by doctors worldwide.[1][3]

The plaintiffs in the case—which include the FTC alongside the attorneys general of Alaska, Iowa, Nebraska, and Texas—argue that WPATH deliberately mischaracterized the medical evidence underpinning its widely adopted standards of care to deceive the public. According to the formal complaint, the organization systematically overstated the role of gender-affirming treatments in reducing suicide rates among youth, while simultaneously understating or obscuring the lifelong medical side effects associated with puberty blockers, hormone therapies, and surgical interventions. The FTC contends that these allegedly misleading guidelines deceived parents and vulnerable patients, ultimately allowing medical providers and the organization's members to prioritize financial profit over children's long-term health and safety.[2][3][5]

WPATH forcefully condemned the lawsuit in a public statement, characterizing the litigation as a politically motivated attack on the independence of professional medical organizations and a blatant violation of First Amendment rights. The organization vigorously defended its clinical guidelines, emphasizing that they have been meticulously developed and refined over more than 50 years. WPATH maintains that its standards are deeply rooted in established scientific evidence, expert consensus, and patient-centered values. Furthermore, the organization clarified that its protocols explicitly do not prescribe a rigid "one-size-fits-all" approach to gender dysphoria; rather, they advocate for comprehensive, individualized care that is carefully tailored to each patient's specific clinical needs and developed through open dialogue between doctors, patients, and families.[1][2][6]

The legal action represents a highly novel and aggressive use of federal consumer protection authority, raising alarms among legal scholars. Lawrence Gostin, a prominent public health law expert at Georgetown University, noted that the FTC has rarely, if ever, utilized its regulatory power to challenge the underlying scientific justifications of a medical association's clinical guidelines. By framing the publication of medical standards as a deceptive trade practice, the administration is attempting to bypass traditional medical consensus mechanisms and peer review. Experts warn that this strategy seeks to directly regulate healthcare standards through the courts, potentially setting a precedent that could allow federal agencies to sue any medical society whose guidelines conflict with the political or ideological priorities of the executive branch.[1][4]

This lawsuit is the latest and most aggressive maneuver in a broader, multi-agency campaign orchestrated by the Trump administration to curtail pediatric gender-affirming care nationwide. Over the past year, the Department of Justice and the FTC have issued a flurry of civil and criminal subpoenas targeting healthcare providers, children's hospitals, and medical societies that support or provide these treatments. In addition to the lawsuit against WPATH, the FTC has launched parallel, wide-ranging investigations into the American Academy of Pediatrics (AAP) and the Endocrine Society regarding their respective guidelines on treating gender dysphoria in minors. Both of those organizations have also filed lawsuits against the federal government in an attempt to block the probes.[2][3][4][5]

The administration's regulatory efforts have already encountered significant judicial resistance prior to this week's filing. Earlier this year, WPATH sued the FTC to halt its underlying investigation, arguing that the agency's invasive demands for internal communications amounted to unconstitutional retaliation for the organization's public advocacy. In May 2026, a federal judge ruled in WPATH's favor, issuing a temporary injunction that successfully blocked the FTC's probe from proceeding. WPATH leadership expressed confidence that this new lawsuit would meet a similar fate, describing the Texas filing as a transparent attempt by the FTC to circumvent the federal court's prior ruling and continue its harassment campaign through a different legal venue known to be amenable to conservative causes.[1][2][5][6]

Despite these legal hurdles and courtroom setbacks, the administration's relentless pressure campaign has yielded concrete disruptions in the American healthcare landscape. The looming threat of federal prosecution, combined with aggressive regulatory action and subpoenas, has created a profound chilling effect among medical providers across the country. Fearing ruinous legal battles, dozens of pediatric clinics have voluntarily shuttered their gender-affirming care programs. Furthermore, major medical institutions, including Texas Children's Hospital and the Cleveland Clinic, have recently entered into high-profile settlements with the government. These agreements commit significant institutional resources to detransitioning services and mandate a decades-long halt on certain gender-affirming treatments for minors, signaling a massive shift in hospital policy driven by federal pressure.[3][4]

The stakes of the Texas lawsuit extend far beyond the operational capacity of WPATH itself, threatening the entire infrastructure of transgender healthcare in the United States. Because the vast majority of major insurance companies base their determinations of medical necessity directly on WPATH's published standards of care, a judicial ruling that invalidates or enjoins these guidelines could have catastrophic downstream effects. If the court agrees that the guidelines are deceptive, it could effectively sever insurance coverage for pediatric gender-affirming care across the country, rendering the treatments financially inaccessible for most families. The FTC and the allied states are explicitly asking the federal judge to issue a permanent injunction against WPATH and to award severe civil penalties and monetary relief.[3][5]

To bolster its claims of deception, the FTC's lawsuit relies heavily on a recent report published by the U.S. Department of Health and Human Services (HHS). The HHS report concluded that the evidence supporting gender-affirming services for children remains weak or inconclusive, recommending psychological interventions over medical ones to minimize potential risks. The complaint also references recent international shifts in pediatric gender medicine to support its case. Specifically, the lawsuit points to comprehensive literature reviews like the United Kingdom's Cass Review, which recently prompted the National Health Service to severely restrict the routine prescription of puberty blockers for minors, arguing that the U.S. medical establishment has ignored global trends in favor of an ideological approach.[3][6]

Despite the mounting federal pressure, major U.S. medical associations—including the American Medical Association, the American Academy of Pediatrics, and the Endocrine Society—continue to broadly endorse gender-affirming care as medically necessary, safe, and life-saving when clinically indicated. However, the legal landscape is rapidly shifting beneath them. With 26 states having already enacted laws restricting or banning the delivery of these services to minors, the FTC's lawsuit threatens to nationalize these restrictions. By leveraging consumer protection laws, the administration is attempting to transform a fractured, state-by-state legislative battle into a sweeping federal mandate, potentially overriding the clinical consensus of the medical community and fundamentally altering the rights of transgender youth nationwide.[3][4]